SCHEMBL1901915

SCHEMBL1901915

O=C(Nc1nnc(-c2ccco2)o1)c1cc(-c2ccccc2F)nc2ccccc12

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 8/20 0.81
CTDSP1 Q9GZU7 1/20 0.62
LMNA P02545 5/20 0.60
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
KDM4E B2RXH2 6/20 0.53
TDP1 Q9NUW8 4/20 0.53
ALDH1A1 P00352 4/20 0.53
HPGD P15428 3/20 0.53
HTT P42858 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
GLA P06280 2/20 0.53
MAPK1 P28482 2/20 0.53
MAPT P10636 2/20 0.53
HCRTR1 O43613 1/20 0.53
L3MBTL1 Q9Y468 3/20 0.52
POLB P06746 2/20 0.52
ESR1 P03372 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1901779 0.90 STAT3 (0.83) STAT3CTDSP1LMNAMEN1KMT2A
SCHEMBL1895922 0.90 STAT3 (1.00) STAT3CTDSP1LMNAMEN1KMT2A
SCHEMBL1899815 0.89 STAT3 (1.00) STAT3CTDSP1LMNAMEN1KMT2A
SCHEMBL1898614 0.89 STAT3 (0.81) STAT3CTDSP1LMNAMEN1KMT2A
SCHEMBL1903545 0.89 STAT3 (0.84) STAT3CTDSP1LMNAMEN1KMT2A
SCHEMBL29382140 0.88 STAT3 (1.00) STAT3CTDSP1LMNAMEN1KMT2A
SCHEMBL1899809 0.88 STAT3 (1.00) STAT3CTDSP1LMNAMEN1KMT2A
SCHEMBL1898038 0.87 STAT3 (0.87) STAT3CTDSP1LMNAMEN1KMT2A
SCHEMBL1900883 0.87 STAT3 (0.74) STAT3CTDSP1LMNAMEN1KMT2A
SCHEMBL1903194 0.86 STAT3 (0.77) STAT3CTDSP1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2325181-B1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2017-03-29 EP disclosed
US-8466290-B2 STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2013-06-18 US disclosed
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2011-07-14 US disclosed
EP-2325181-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT Pharma Ip General Incorporated Association (JP) 2011-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT STAT3, STAT4, STAT5B STAT3 1/4885CTDSP1 1127/4885LMNA 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.